SRPK1 and cancer: The synthesized (JH-VII-139-1)-c(RGDyK) conjugates retained the inhibitory activity of JH-VII-139-1 against SRPK1, while exhibiting different cytotoxicity profile against cancer cells expressing integrins to various extend.